News

Show
news from

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

Load more

Search